Biphasic calcium phosphate tied to higher graft volume stability in lateral window sinus floor elevation
Biphasic calcium phosphate tied to higher graft volume stability in lateral window sinus floor elevation suggests a new study published in the Clinical Oral Implants Research.
A study was done to assess in a prospective randomised trial two psychogenic bone substitutes—biphasic calcium phosphate (BCP) versus almost pure hydroxyapatite (HA)—for their volume stability and clinical implications after sinus floor elevation (SFE). Twenty patients requiring lateral-window sinus floor elevation 6 months before implant surgery were randomized to a biphasic calcium phosphate or hydroxyapatite group. As the primary outcome, the grafts were analyzed for volume stability, using four cone-beam computed tomography scans obtained immediately/6/12/24 months after sinus floor elevation. Secondary outcomes were implant survival, success, periotest values, oral-health-related quality of life (OHIP-G14), and pain (VAS).Results: Kolmogorov–Smirnov goodness-of-fit test revealed normal distribution of samples (p = .200). At 6/12/24 months, the augmented volumes decreased to 96/92/90% (HA) or 99/96/96% (biphasic calcium phosphate). Volume changes were significantly a factor of time and reached significantly lower values in the hydroxyapatite group. The significant intergroup difference in volume losses was notable at 24 months (p = .021; t-test for independent samples). Periotest values decreased from −3/−4.1 (HA/BCP) after implant placement to −6.3/−4.5 (HA/BCP) after 6 months. OHIP scores diverged at 2 months and largely resolved by 24 months. VAS scores were comparable, 2.2 at 1 week after sinus floor elevation being their highest mean level. After 2 years, both groups experienced no biological or technical complications, demonstrating a consistent healing trajectory without notable symptoms. Although no significant differences were observed in implant stability and survival, biphasic calcium phosphate demonstrated higher volume stability than hydroxyapatite.
Reference: Sokolowski, A., Theisen, K., Arefnia, B., Payer, M., Lorenzoni, M., & Sokolowski, A. (2023). A randomized clinical trial of phycogenic materials for sinus grafting with hydroxyapatite versus biphasic calcium phosphate: 2 years clinical outcomes. Clinical Oral Implants Research, 00, 1–12. https://doi.org/10.1111/clr.14209
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd